Literature DB >> 9498932

Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

J M DeCara, S Croze, R H Falk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9498932     DOI： 10.1378/chest.113.2.261

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  Barriers to the use of warfarin: potential solutions.

Authors:  John H McAnulty
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

2.  Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.

Authors:  Michael A Fischer; Jerry Avorn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

3.  Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.

Authors:  Nicole Mittmann; Paul I Oh; Scott E Walker; William R Bartle
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.